http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011105409-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1647 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-712 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate | 2009-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011105409-A |
| titleOfInvention | METHOD FOR TREATING ATROPHIC AGE-RELATED MACULAR DEGENERATION |
| abstract | 1. A biocompatible drug delivery system containing an antineovascular agent, an antivascular agent of vascular endothelial growth factor (anti-FRES), selected from the group consisting of bevacizumab, ranibizumab and pegaptanib and their derivatives, esters, salts and mixtures, and polymer a carrier associated with an antineovascular agent, where the polymer carrier is a copolymer of lactic and glycolic acids (PLPP), for use in a method for treating age-related dry yellow degeneration yatna (dry VZHP), including the stage of introducing the drug delivery system into the eye of a patient with dry VZHP, thus curing dry VZHP. ! 2. The drug delivery system for use according to claim 1, wherein the antineovascular agent is associated with the polymer carrier, being dispersed homogeneously in the polymer carrier. ! 3. The drug delivery system for use according to claim 1, where the stage of administration is performed by injection of an antineovascular agent into the anterior region of the eye. ! 4. The drug delivery system for use according to claim 1, where the stage of administration is performed by injection of an antineovascular agent into the posterior region of the eye. ! 5. The drug delivery system for use according to claim 4, where the stage of administration is performed by injection of an antineovascular agent into the vitreous cavity. ! 6. The drug delivery system for use according to claim 1, where the antineovascular agent is bevacizumab or its derivative, ester or salt. ! 7. The drug delivery system for p |
| priorityDate | 2008-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.